MDT-AP-0809
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 35.160000000000004
- os_event
- true
- age_years
- 12.57
- sex
- M
- new_clusters
- C4
- umap1_2d
- 3.696783018
- umap2_2d
- 3.923706777
- umap1_3d
- 0.796408729
- umap2_3d
- -0.662626221
- umap3_3d
- -1.166959749
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_GAMMA_RESPONSE+0.430
- INTERFERON_ALPHA_RESPONSE+0.400
- PANCREAS_BETA_CELLS+0.390
- ANGIOGENESIS+0.380
- E2F_TARGETS+0.350
- DNA_REPAIR+0.340
- INFLAMMATORY_RESPONSE+0.340
- G2M_CHECKPOINT+0.320
Top 10 suppressed
- MYC_TARGETS_V2-0.310
- PROTEIN_SECRETION-0.290
- TGF_BETA_SIGNALING-0.220
- HEME_METABOLISM-0.210
- MITOTIC_SPINDLE-0.120
- WNT_BETA_CATENIN_SIGNALING-0.120
- HEDGEHOG_SIGNALING-0.060
- UV_RESPONSE_UP-0.060
- BILE_ACID_METABOLISM-0.030
- UNFOLDED_PROTEIN_RESPONSE-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0732 | Med | Medulloblastoma | 0.855 |
| 2 | MDT-AP-0565 | Med | Medulloblastoma | 0.849 |
| 3 | MDT-AP-2390 | Med | Medulloblastoma | 0.822 |
| 4 | MDT-AP-0049 | Med | Medulloblastoma | 0.809 |
| 5 | MDT-AP-2131 | Med | Medulloblastoma | 0.807 |
| 6 | AUR-AFUG-TTM1-A-1-1-R-A743-41 | — | C | 0.780 |
| 7 | TCGA-UY-A78P-01A-12R-A36F-07 | — | — | 0.776 |
| 8 | 608d8ca8-8eeb-40a1-a95b-57eefcabbdab | — | — | 0.771 |
| 9 | MDT-AP-2102 | Med | Medulloblastoma | 0.769 |
| 10 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |